Biotech
- Article Tools
- Email this Article
- Print this Article
- Rss Feed
- Related Articles
- Vertex Shares Face Long Road Back to Recovery
- Nastech, P&G Part Ways on Bone Drug
- Onyx Pharma Posts Profit
- Del.icio.us
- Digg
- StumbleUpon
Abraxis BioScienceABBI missed on third-quarter earnings and revenue as it prepares to separate its surging Abraxane business from its more sluggish hospital-based product segment. The biopharmaceutical company on Thursday reported adjusted earnings of $23.1 million, or 15 cents a share, up from $16.7 million, or 10 cents a share, in the year-ago period. And the company reported revenue of $241 million, up from $203.1 million in the 2006 quarter but falling shy of the Thomson Financial analyst estimates of 22 cents a share on revenue of $253.9 million. Sales of breast cancer treatment Abraxane increased 65% to $86.4 million, vs. $52.3 million in the 2006 period. The Los Angeles-based company's hospital-based product revenue from the company's Abraxis Pharmaceutical Products (APP) segment, increased just 2.3% to $153.2 million from $149.8 million in the 2006 quarter. Abraxis said annual revenue for the segment is now expected to increase about 9% year over year -- the lower end of a previous guidance range. The company previously announced it is spinning the APP segment off into a separate, publicly traded business, and said Thursday that the transaction will close on Nov. 13. Abraxane is included in the new Abraxis BioScience (ABI). Shares fell $2.21, or 9.1%, to $22.01.
Winning back investors isn't totally within the company's control.
Nastech regains rights to the Teriparatide nasal spray for osteoporosis.
The penny per-share profit beats Wall Street estimates.
Yahoo! is among the most searched stocks on TheStreet.com. Here's what Cramer had to say about the stock recently.
Catch up on his thinking on the hottest topics of the past week.
Investors will have to deal with a Fed meeting and another flood of earnings and economic data.
Ensco International and Echelon have the potential to move higher in coming days.
See who made what calls.
The addition of video is helping telecom companies compete against cable and satellite companies.
The June West Texas Intermediate contract reflects selling pressure ahead of Tuesday's expiration. But stocks in the sector are generally trading higher.
See who made what calls.
Keep on top of the market and the critical information you need to make more profitable investing decisions.
Sponsored by:
RSS
